Professor Johann de Bono and his team at the ICR and The Royal Marsden NHS Foundation Trust carried out the initial clinical development on this drug, as well as leading the later-stage international clinical trials including the first trial that led to regulatory approval.

Abiraterone is now used as standard treatment either before or after chemotherapy and has extended the lives of thousands of men in the UK with advanced prostate cancer.